Prostate targeting: PSP94 gene promoter/enchancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model

Gene Therapy

Volumn 9, Issue 23, 2002, Pages 1589-1599

  Gabril, M Y ^a,b   Onita, T ^a,c   Ji, P G ^a   Sakai, H ^c   Chan, F L ^b   Koropatnick, J ^a,b   Chin, J L ^a   Moussa, M ^b   Xuan, J W ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Prostate targeting; PSP transgenic mice; PSP94 microseminoprotein; Transgenic mouse

Indexed keywords

ANDROGEN; BETA GALACTOSIDASE; SECRETORY PROTEIN;

AGE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRADING; CARCINOGENESIS; CELL CULTURE; CONTROLLED STUDY; DELETION MUTANT; ENHANCER REGION; FEMALE; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HISTOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MARKER GENE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PUBERTY; REPORTER GENE; SIMIAN VIRUS 40; TISSUE SPECIFICITY; TRANSGENE; TRANSGENIC MOUSE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENHANCER ELEMENTS (GENETICS); GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TARGETING; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, TRANSGENIC; NEOPLASM METASTASIS; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; PROSTATIC SECRETORY PROTEINS; TRANSGENES; TUMOR CELLS, CULTURED;

ADENOVIRIDAE; ANIMALIA; MUS MUSCULUS; RODENTIA; SIMIAE; SIMIAN VIRUS; SIMIAN VIRUS 40;

EID: 0036892926     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301895     Document Type: Article

References (41)

1. Steiner MS, Gingrich JR. Gene therapy for prostate cancer: where are we now? J Urol 2000; 164: 1121-1136.
2. Kitsberg DI, Leder P. Keratinocyte growth factor induces mammary and prostatic hyperplasia and mammary adenocarcinoma in transgenic mice. Oncogene 1996; 13: 2507-2515.
3. Garabedian EM, Humphrey PA, Gordon JI. A transgenic mouse model of metastatic prostate cancer originating from neroendocrine cells. Proc Natl Acad Sci USA 1998; 62: 227-237.
4. Perez-Stable C et al. Prostate cancer progression, metastasis, and gene expression in transgenic mice. Cancer Res 1997; 57: 900-906.
5. DiGiovanni J et al. Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci USA 2000; 97: 3455-3460.
6. Blackburn RV, Galoforo SS, Corry PM, Lee YJ. Adenoviral-mediated transfer of a heat-inducible double suicide gene into prostate carcinoma cells. Cancer Res 1998; 58: 1358-1362.
7. Sharma P, Schreiber-Agus N. Mouse models of prostate cancer. Oncogene 1999; 18: 5349-5355.
8. Matusik RJ et al. Transgenic mouse models of prostate cancer. In: Matuk M, Brown CW, Kumar TR (eds). Comtemporary Endocrinology: Transgenics in Endocrinology. Humana Press: Totowa, 2001, pp 401-425.
9. Green JE et al. Workgroup 3: transgenic and reconstitution models of prostate cancer. Prostate 1998; 36: 59-63.
10. Maroulakou IG, Anver M, Garrett L, Green JE. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci USA 1994; 91: 11236-11240.
11. Shibata MA et al. Progression of prostatic intraepithelial neoplasia to invasive carcinoma in C3(1)/SV40 large T antigen transgenic mice: histopathological and molecular biological alterations. Cancer Res 1996; 56: 4894-4903.
12. Shibata MA et al. Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40-TAg transgenic mice: reduction in protective apoptotic response at the preneoplastic stage. EMBO J 1999; 18: 2692-2701.
13. Rodriguez R et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate - specific antigen-positive prostate cancer cells. Cancer Res 1997; 57: 2559-2563.
14. Pang S et al. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. Cancer Res 1997; 57: 495-499.
15. Schuur ER et al. Prostate-specific antigen expression is regulated by an upstream enhancer. J Biol Chem 1996; 271: 7043-7051.
16. Schaffner DL et al. Transgenic mice carrying a PSArasT24 hybrid gene develop salivary gland and gastrointestinal tract neoplasms. Lab Invest 1995; 72: 283-290.
17. Cleutjens KB et al. A 6-kb promoter fragment mimics in transgenic mice the prostate-specific and androgen-regulated expression of the endogenous prostate-specific antigen gene in humans. Mol Endocrinol 1997; 11: 1256-1265.
18. Wei C et al. Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy. Proc Natl Acad Sci USA 1997; 94: 6369-6374.
19. Gingrich JR et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996; 56: 4096-4102.
20. Greenberg NM, Demayo F, Finegold MJ et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995; 92: 3439-3443.
21. Gingrich JR et al. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 1997; 57: 4687-4691.
22. Kasper S et al. Development, progression and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Lab Invest 1998; 78: 319-333.
23. Zhang J, Thomas TZ, Kasper S, Matusik RJ. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 2000; 141: 4698-4710.
24. Wu X et al. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev 2001; 101: 61-69.
25. Hsieh CL, Yang L, Miao L et al. A novel targeting modality to enhance adenoviral replication by vitamin D(3) in androgen-independent human prostate cancer cells and tumors. Cancer Res 2002; 62: 3084-3092.
26. Matsubara S et al. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res 2001; 61: 6012-6019.
27. Yu DC et al. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res 2001; 61: 517-525.
28. Latham JPF, Searle PF, Mautner V, James ND. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue specific adenovirus vector. Cancer Res 2000; 60: 334-341.
29. Yu DC, Sakamoto GT, Henderson DR. Identification of the transcriptional regulatory sequences of human Kalilkrein 2 and their use in the construction of Calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res 1999; 59: 1498-1504.
30. Hara M, Kimura H. Two prostate-specific antigens, -seminoprotein and β-microseminoprotein. J Lab Clin Med 1989; 113: 541-548.
31. Wu D et al. Serum bound forms of PSP94 (prostate secretory protein of 94 amino acids) in prostate cancer patients. J Cell Biochem 1999; 76: 71-83.
32. Imasato Y et al. PSP94 expression after androgen deprivation therapy: a comparative study with prostate specific antigen in benign prostate and prostate cancer. J Urol 2000; 164: 1819-1824.
33. Imasato Y et al. Rodent PSP94 gene expression is more specific to the dorsolateral prostate and less sensitive to androgen ablation than probasin. Endocrinol 2001; 142: 2138-2146.
34. Bauman GS et al. PSP94: evaluation of prognostic utility in patients treated with radiotherapy for nonmetastatic prostate cancer. Prostate J 2000; 2: 94-101.
35. Xuan JW et al. cDNA, genomic cloning and gene expression analysis of mouse PSP94 (prostate secretory protein of 94 amino acids). DNA Cell Biol 1999; 18: 11-26.
36. Palmiter RD et al. Heterologous introns can enhance expression of transgenes in mice. Proc Natl Acad Sci USA 1991; 88: 478-482.
37. Yu DC et al. The addition of adenovirus type 5 region E3 enables Calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res 1999; 59: 4200-4203.
38. Yan Y et al. Large fragment of the probasin promoter targets high levels of transgene expression to the prostate of transgenic mice. Prostate 1997; 32: 129-139.
39. Hogan B, Beddington R, Costantini F, Lacy E. Manipulating the Mouse Embryo: A Laboratory Manual. In: Cold Spring Harbor Laboratory: New York 1994.
40. Xuan JW et al. Alternative splicing of PSP94 (prostate secretory protein of 94 amino acids) mRNA in prostate tissue. Oncogene 1995; 11: 1041-1047.
41. Xuan JW et al. Molecular cloning and gene expression analysis of PSP94 (prostate secretory protein of 94 amino acids) in primates. DNA Cell Biol 1997; 16: 627-638.